期刊文献+

促红细胞生成素原核表达载体构建分离纯化

Vector construction,expression and purification of erythropoietin
下载PDF
导出
摘要 目的构建和表达人源性促红细胞生成素(EPO),为促红细胞生成素发挥功能与结构差异研究做准备。方法通过NCBI查找人源性促红细胞生成素全基因序列并合成,构建原核表达载体pTWIN1-rhEPO,转化至大肠杆菌BL21(DE3),获得高效表达重组转化子菌株。结果成功构建人源性促红细胞生成素原核表达载体,经酶切和DNA序列测序分析,结果表明该基因序列与合成序列完全相同。终浓度0.5mmol/L ITPG诱导表达,SDS-PAGE电泳分析,4小时时蛋白表达量最高。结论构建和表达重组载体pTWIN1-rhEPO,分离纯化出目的蛋白,为进一步研究促红细胞生成素组织修复功能及突变体相关功能研究奠定基础。 Objective To construct and express the human-derived erythropoietin in order to study the differences in structure and function for the further research. Methods The rhEPO sequence was identified through NCBI and was synthesized, constructed Prokaryotic expression vector pTWINI-rhEPO, transformed into E. coli BL21 (DE3), to obtain efficient expression of recombinant transformant strains respectively. Results Successfully constructed human-derived erythropoietin prokaryotic expression vector, as a result of digestion and DNA sequencing analysis showed that the gene sequence was identical with the synthetic sequence. The final concentration of 0.5mmol/L IPTG was used to induce protein expression, SDS-PAGE electrophoresis analysis, protein expression was highest at 4h. Conclusion Constructed and expressed the Prokaryotic expression vector pTWINI-rhEPO, utilized chitin affinity chromatography to separate and purify of rhEPO, for further study of erythropoietin tissue repair functions and the mutants' related functions do research foundation.
出处 《西部医学》 2015年第8期1131-1134,共4页 Medical Journal of West China
基金 国家基础科学人才培养基金(J1103604)
关键词 促红细胞生成素 表达载体构建 原核表达 分离纯化 Erythropoietin Expression vector construction Prokaryotic expression Separation and purification
  • 相关文献

参考文献12

  • 1Rizzo JD,M Brouwers,P. Hurley,etal. American Society of He- matology and the American Society of Clinical Oncology Practice Guideline Update Committee[J]. American Society of Hematol- ogy/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer [J]. Blood, 2010, 116: 4045-4059.
  • 2张胜叶,黄晏,张锦,牛欢,赵乾,李一佳.内源性促红细胞生成素在急性心肌梗死介入前后的动态变化及心肌保护作用和抗炎作用[J].实用医学杂志,2011,27(17):3124-3127. 被引量:2
  • 3钟顺平,李景铧,李前进.促红细胞生成素对难愈创面患者康复的影响[J].西部医学,2014,26(10):1354-1356. 被引量:7
  • 4Mammis A, McIntosh TK, Maniker AH,et al. Erythropoietin as a neuroprotective agent in traumatic brain injury [J]. Surg Neurol, 2009, 71(5): 527-531.
  • 5齐帅,宋鹏飞.血清促红细胞生成素与急性心肌梗死的关系研究[J].西部医学,2010,22(12):2327-2328. 被引量:4
  • 6Yoshmiura A, Zmimers T, Neumann D, et al. Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish processing, ligand binding, and activation of the receptor [J]. Biol Chem, 1992, 267(16): 11619-11625.
  • 7Szenajch J, G. Wcislo JY, Jeong C,et al. The role of erythro- poietin and its receptor in growth, survival and therapeutic re- sponse of human tumor cells From clinic to bench- a critical re- view [J]. Biochim. Biophys, 2010, 1806: 82-86.
  • 8Wojchowski DM,P. Sathyanarayana, and A. Dev,et al. Eryth- ropoietin receptor response circuits [J]. Curt. Opin. Hematol, 2010, 17(3): 169-176.
  • 9王锋,柴璐,范亚平,杨斌,范凤燕,黄新忠,张义德.促红细胞生成素衍生肽治疗顺铂所致急性肾损伤的使用方法探讨[J].实用医学杂志,2013,29(17):2781-2783. 被引量:3
  • 10Gan Y. Mutant erythropoietin without erythropoietic activity is neuroprotective against isehemic brain injury [J]. Stroke, 2012, 43(11): p. 3071-3077.

二级参考文献45

  • 1张兆新,吕磊,刘小龙,刘利华,张亮,纪东亮,查天建.重组人表皮生长因子凝胶在慢性难愈性溃疡创面中的应用研究[J].中华临床医师杂志(电子版),2011,5(8):2186-2190. 被引量:20
  • 2赵玉伟,李法琦.促红细胞生成素与心血管疾病[J].心血管病学进展,2006,27(1):41-44. 被引量:3
  • 3徐良,孙仁华.EPO心肌保护作用与机制的研究进展[J].浙江中医药大学学报,2007,31(2):255-256. 被引量:2
  • 4Saraste A, Pulkki K, Kallajoki M, etal. Apoptosis in human acute myocardial infarction[J]. Circulation, 1997,95 (2) : 320 - 323.
  • 5Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction[J]. J Pharmacol Science,2006, 101 (1)31-39.
  • 6Namiuchi S, Kagaya Y, Ohta J, etal. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention [J].J Am Coil Cardiol, 2005, 45(9) : 1406-1412.
  • 7Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phophatidylinosito123 kinase2dependent pathway in canine hearts[J]. Cardiovasc Drugs Ther, 2005, 19 (1) 33-40.
  • 8Ruifrok W P, Lipsic E, de Boer R A, et al. Erythropoiesis stimulation in acute ischemic syndromes [J]. Heart Fail Clin, 2010,6(3) :313-321.
  • 9Namiuchi S, Kagaya Y, Ohta J, el al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary pereutaneous coronary intervention [J]. J Am Coil Cardiol, 2005,45(9) : 1406-1412.
  • 10Ghaboura N, Tamareille S, Ducluzeau P H, el al. Diabetes mellitus abrogates erythropoietin-induced eardioprotection against ischemic-reperfusion injury by aheration of' the RISK/ GSK-313 signaling [J]. Basic Res Cardiol, 2011,106( 1 ) : 147- 162.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部